Sarepta Therapeutics Inc SRPT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress
-
Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors
-
Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year
-
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
-
Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments
-
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $118.76
- Day Range
- $118.63–121.88
- 52-Week Range
- $55.25–173.25
- Bid/Ask
- $119.16 / $122.00
- Market Cap
- $11.48 Bil
- Volume/Avg
- 893,683 / 1.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- 51.02
- Price/Sales
- 7.82
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 1,314
- Website
- https://www.sarepta.com
Comparables
Valuation
|
Metric
|
SRPT
|
CTNM
|
RCKT
|
|---|---|---|---|
Price/Earnings (Normalized) | 51.02 | — | — |
Price/Book Value | 10.65 | 2.01 | 3.88 |
Price/Sales | 7.82 | — | — |
Price/Cash Flow | 41.51 | — | — |
Price/Earnings
SRPT
CTNM
RCKT
Financial Strength
|
Metric
|
SRPT
|
CTNM
|
RCKT
|
|---|---|---|---|
Quick Ratio | 2.69 | 58.48 | 7.42 |
Current Ratio | 3.90 | 58.92 | 7.79 |
Interest Coverage | −0.13 | — | −143.43 |
Quick Ratio
SRPT
CTNM
RCKT
Profitability
|
Metric
|
SRPT
|
CTNM
|
RCKT
|
|---|---|---|---|
Return on Assets (Normalized) | 7.18% | −18.15% | −41.09% |
Return on Equity (Normalized) | 26.33% | −871.68% | −46.72% |
Return on Invested Capital (Normalized) | 8.09% | −892.99% | −47.69% |
Return on Assets
SRPT
CTNM
RCKT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Hdhvwxcl | Xdh | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Tcgbnmfq | Sqqwgh | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Sfkbkrlq | Bvygtvm | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Cpjvxyrdb | Lbllf | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Flvgfmqw | Lrhtc | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Zknzkpjr | Djryw | $29.2 Bil | |||
| Moderna Inc
MRNA
| Wrwhnrt | Gsnt | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Rcwjdklnm | Wdxy | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Rydycmwk | Qhssc | $13.2 Bil | |||
| Incyte Corp
INCY
| Dndfzxkw | Tzbhfm | $13.0 Bil |
United States